Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Update

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) saw a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 1,000 shares, a drop of 28.6% from the May 15th total of 1,400 shares. Based on an average daily trading volume, of 8,100 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the company’s stock are short sold.

Invesco Biotechnology & Genome ETF Stock Up 0.9%

Shares of NYSEARCA:PBE opened at $64.52 on Tuesday. Invesco Biotechnology & Genome ETF has a 52-week low of $54.52 and a 52-week high of $72.84. The stock has a market cap of $228.40 million, a price-to-earnings ratio of 20.39 and a beta of 0.79. The business has a 50-day moving average price of $61.69 and a 200-day moving average price of $65.15.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Banque Cantonale Vaudoise acquired a new stake in Invesco Biotechnology & Genome ETF in the first quarter valued at approximately $34,000. JPMorgan Chase & Co. grew its holdings in Invesco Biotechnology & Genome ETF by 30.0% in the fourth quarter. JPMorgan Chase & Co. now owns 650 shares of the company’s stock valued at $43,000 after purchasing an additional 150 shares during the period. Millstone Evans Group LLC acquired a new stake in Invesco Biotechnology & Genome ETF in the fourth quarter valued at approximately $64,000. Capital Analysts LLC grew its holdings in Invesco Biotechnology & Genome ETF by 55.9% in the fourth quarter. Capital Analysts LLC now owns 1,715 shares of the company’s stock valued at $114,000 after purchasing an additional 615 shares during the period. Finally, Jones Financial Companies Lllp grew its holdings in Invesco Biotechnology & Genome ETF by 52.9% in the fourth quarter. Jones Financial Companies Lllp now owns 2,315 shares of the company’s stock valued at $154,000 after purchasing an additional 801 shares during the period.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.